Accelerated clearance of PEGylated liposomes in rats after repeated injections

Journal of Controlled Release

Volumn 88, Issue 1, 2003, Pages 35-42

  Ishida, Tatsuhiro ^a   Maeda, Ryuhei ^a   Ichihara, Masako ^a   Irimura, Kenji ^b   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Accelerated clearance effect; PEGylated liposomes; Polyethylene glycol (PEG); Repeated injection

Indexed keywords

LIPOSOME; POLYETHYLENE GLYCOL MODIFIED LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CIRCULATION TIME; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG USE; EVOKED RESPONSE; HUMORAL IMMUNITY; INJECTION; KUPFFER CELL; LIVER; MALE; NONHUMAN; PHENOMENOLOGY; PLASMA TRANSFUSION; PRIORITY JOURNAL; RAT; SERUM FACTOR;

EID: 0037436030     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00462-5     Document Type: Article

References (20)

1. Allen T.M., Hansen C.B. Pharmacokinetics of Stealth versus conventional liposomes: effect of dose. Biochim. Biophys. Acta. 1068:1991;133-141.
2. Senior J.H. Fate and behaviour of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3:1987;123-193.
3. Patel H.M. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;39-90.
4. Woodle M., Lasic D. Sterically stabilized liposomes. Biochim. Biophys. Acta. 1113:1992;171-199.
5. Martin F.J. Lasic D.D., Papahadjopoulos D. Clinical Pharmacology and Antitumor Efficacy of DOXIL (PEGylated Liposomal Doxorubicin). Medical Applications of Liposomes. 1998;635-688 Elsevier, Amsterdam.
6. Dams E.T.M., Laverman P., Oyen W.J.G., Storm G., Scherphof G.L., Van der Meer J.W.M., Corstens F.H.M., Boerman O.C. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 292:2000;1071-1079.
7. Lopes de Menezes D.E., Pilarski L.M., Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58:1998;3320-3330.
8. Bartlett G.R. Phosphorus assay in column chromatography. J. Biol. Chem. 234:1959;466-468.
9. Harashima H., Yamane C., Kume Y., Kiwada H. Kinetic analysis of AUC-dependent saturable clearance of liposomes: mathematical description of AUC dependency. J. Pharm. Biopharm. 21:1993;299-308.
10. Mayer M.M. Kabat E.A., Mayer M.M. Complement and Complement Fixation. Experimental Immunochemistry. 1961;133-240 Charles C. Thomas, Springfield, IL.
11. Devine D.V., Marjan J.M. The role of immunoproteins in the survival of liposomes in the circulation. Crit. Rev. Ther. Drug. Carrier Syst. 14:1997;105-131.
12. Harashima H., Matsuo H., Kiwada H. Identification of proteins mediating clearance of liposomes using a liver perfusion system. Adv. Drug Deliv. Rev. 32:1998;61-79.
13. Szebeni J. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carrier Syst. 15:1998;57-88.
14. Gordon A.N., Granai C.O., Rose P.G., Hainsworth J., Lopez A., Weissman C., Rosales R., Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 18:2000;3093-3100.
15. Halm U., Etzrodt G., Schiefke I., Schmidt F., Witzigmann H., Mossner J., Berr F. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann. Oncol. 11:2000;113-114.
16. Hubert A., Lyass O., Pode D., Gabison A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs. 11:2000;123-127.
17. Allen T.M. Liposome targeting in animal models: problems and opportunities. J. Liposome Res. 7:1997;315-329.
18. Sparano J.A., Winer E.P. Liposomal anthracyclins fir breast cancer. Semin. Oncol. 4:(Suppl. 12):2001;32-40.
19. Vanetten E.W.M., Vanvianen W., Tijhuis R.H.G., Storm G., Bakkerwoudenberg I.A.J.M. Sterically stabilized amphotericin B liposomes: toxicity and biodistribution in mice. J. Control. Release. 37:1995;123-129.
20. Vanetten E.W.M., Ottelambillion M., Vanvianen W., Tenkate M.T., Bakkerwoudenberg I.A.J.M. Biodistribution of liposomal amphotericin B (ambisome) and amphotericin B desoxycholate (fungizone) in uninfected immunocompetent mice and leucopenic mice infected with candida albicans. J. Antimicrobial Chemother. 35:1995;509-519.